Skip to main content
Signal8

AUNA S.A. (AUNA) Form 6-K — Nov 17, 2026

$AUNAForm 6-KFiled Nov 17, 2026, 5:28 PM ET0000950103-26-017687Original filing

Auna reported 3Q26 revenue of S/1,325 million, up 19% YoY as reported and 10% FX-neutral, with growth across all three markets. Adjusted EBITDA, however, fell 4.6% FX-neutral to S/231 million with a 17.5% margin, pressured by Colombia and Peru. The company cut its full-year 2026 Adjusted EBITDA guidance to 'broadly stable or slightly down' year-over-year, down from prior guidance of 10-14% FX-neutral growth, citing adverse medical costs under a terminated oncology risk-sharing contract in Colombia and government price caps on high-cost oncology drugs. Revenue guidance of 10-14% FX-neutral growth was reaffirmed.

Key figures

Eps
0.27
Revenue
1325000000
Guidance
FY26 revenue growth reaffirmed at 10-14% FX-neutral; Adjusted EBITDA revised down to broadly stable or slightly down YoY (from 10-14% FXN growth); capex ~4% of revenues
Net Income
24000000
Total Debt
3746000000
Revenue Yoy
19% as reported / 10% FX-neutral
Cash Position
614000000
Surgeries q
23932
Leverage ratio
3.5x
Net debt pen m
3133
Adjusted ebitda pen m
231
Free cash flow ytd pen m
626
Adjusted net income pen m
35
Adjusted ebitda margin pct
17.5
Free cash flow growth yoy pct
95
Operating cash flow ytd pen m
713
Operating cash flow growth yoy pct
62
Mexico segment ebitda change lc pct
5
Colombia segment ebitda change lc pct
-30

AI analysis

Red flags6 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.